Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
Last trade$4.54
Day change-$0.07 (-1.52%)
Day range$4.53 – $4.63
Volume589,938
Market cap$303M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ACB.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ACB.
Recent news
Company coverage with links to the original publishers.
Tilray Brands has not made a bid for Aurora Cannabis despite being an acquisition-hungry company, as its strategic focus has shifted toward U.S. beverage acquisitions and craft brewing rather than expanding in the competitive Canadian cannabis market. The company recently announced consolidation efforts in Canada to focus on profitability, making a major acquisition of a Canadian producer like Aurora less attractive to its long-term strategy.
Organigram agreed to acquire Aurora Cannabis at a 21% premium over Curaleaf's hostile takeover offer. However, the article argues that Curaleaf emerges as the real winner because the combined Organigram-Aurora entity will be more entrenched in the declining Canadian recreational cannabis market. Curaleaf, with stronger financials and U.S. operations, may eventually acquire the combined company at a lower valuation if the deal underperforms.
An analysis of five major cannabis stocks reveals significant differences in financial health. Cronos Group leads with approximately $841 million in cash and no significant debt, followed closely by SNDL, which is debt-free with positive free cash flow. Tilray and Canopy Growth continue to struggle with debt and negative cash flow despite some revenue growth, while Aurora Cannabis has a smaller liquidity cushion. A strong balance sheet provides financial flexibility but doesn't guarantee profitability or shareholder returns.
SNDL Inc. reported mixed Q3 2026 results with revenues beating estimates at $170.1 million but adjusted loss per share wider than expected. The company is intensifying shareholder returns through 5.4 million share repurchases and exploring a C$50 million issuer bid. SNDL increased its Parallel ownership to 92% to expand U.S. medical cannabis exposure, though margin pressure and weak cannabis sales persist, with management implementing cost-reduction measures.
Aurora Cannabis is expected to report Q2 fiscal 2027 revenues of $52.5 million, down 20.1% year-over-year, due to strategic exits from lower-margin Canadian markets and a 30% cut in Canadian reimbursement rates. However, the company is seeing growth support from strong German demand and expansion opportunities in Poland and Australia through its Safari Flower Company acquisition.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 19, 2007
$1.05
Dec 31, 2007
unknown
Dec 19, 2007
$3.78
Dec 31, 2007
unknown
Dec 19, 2007
$18.7392
Dec 31, 2007
unknown
Stock splits
Historical share-structure events and their execution dates.